Of note, a study from Gabriel group conducted in vivo epigenetic CRISPR screens using mouse tumor models to systematically identify chromatin regulators influencing tumor immunity and the efficacy of ICB therapies,[3] SIN3B emerged as one of the potential negative candidates of anti‐tumor immunity. The gene discussed is SIN3B; the disease is neoplasm.